대한한방내과학회지 (The Journal of Internal Korean Medicine)

대한한방내과학회 (The Society of Internal Korean Medicine)
권호 표지

오령산 효능에 관한 기초 실험 연구 문헌 분석

Analysis of biological experiment on Oryeong-san (Wuling-san)

  • 김정훈 (한국한의학연구원 한약기초연구그룹) ;
  • 신현규 (한국한의학연구원 한약기초연구그룹)
  • Kim, Jung-Hoon (Basic Herbal Medicine Research Group, Korea Institute of Oriental Medicine) ;
  • Shin, Hyeun-Kyoo (Basic Herbal Medicine Research Group, Korea Institute of Oriental Medicine)
  • 발행 : 2012.03.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objectives : To establish objective and scientific evidence of Korean medicine (KM), the papers on Oryeong-san (Wuling-san) frequently used in medical institutions of Korean Medicine were analyzed. Methods : The papers were classified by the registration of domestic or international journals, the year of publication, experimental fields and the kinds of studies on biological activities. The therapeutic mechanism was investigated in accordance with therapeutic effect of Oryeong-san (Wuling-san). Results : Out of 57 articles selected, 16 were published in domestic journals, 17 were in Chinese journals and 24 were in Japanese journals. Most papers reported as biological activities were on improvement of renal function. Oryeong-san (Wuling-san) increased urine factor such as urine excretion and electrolyte balance while decreasing proteinuria, serum factors including creatinine, cholesterol and triglyceride. In addition, injured renal tissue was recovered normally and gene expression controlling urine excretion was down-regulated. Conclusions : Improvement of renal function could be interpreted as objective and scientific evidence for Oryeong-san (Wuling-san).

키워드

참고문헌

  1. 한의과대학 방제학교수 공편저. 방제학. 서울: 영림사; 2003, p. 504-6.
  2. 박요한, 황대선, 신현규. 한방의료기관 한약제제 구비 현황 조사 연구. 대한한의학방제학회지 2010;18(1):43-56.
  3. 李尙仁. 五苓散 및 加味五苓散이 家兎利尿 作用에 미치는 영향. 경희대학교 한의학과 박사학위논문. 1980.
  4. 田中 重雄, 晶 利明, 田端 守. 五苓散料の藥理活性に基づく處方解析. 藥學雜誌 1984;104(6):601-6.
  5. 朴炫局, 申玟圭. 家免의 利尿와 尿成分 變化에 미치는 五苓散 및 四物湯의 影響. 동서의학 1985;10(2):18-30.
  6. 林準圭. 五苓散 煎湯液이 白鼠의 血淸 電解質 變化에 미치는 影響. 대전대학교 한의학과 석사학위 논문. 1990.
  7. 安世永. 五苓散 및 六味地黃湯이 Gentamicin Sulfate로 誘發된 白鼠의 急性腎不全에 미치는 影響. 경희대학교 한의학과 박사학위논문. 1993.
  8. 任昤該. 五苓散, 六味地黃湯, 補中益氣湯, 人蔘敗毒散이 Gentamicin Sulfate로 損傷시킨 白鼠의 腎組織 病變에 미치는 影響. 경희대학교 한의학과 석사학위 논문. 1995.
  9. 中西 由香, 織田 眞智子, 唐方, 阿部 博子. 利水劑としての五苓散の作用第 3 報. The general meeting of Medical and Pharmaceutical Society for Wakan-yaku 1995;12:41.
  10. 周聯, 陣芝喜. 五苓散及其組分對正常小鼠血漿心納素含量的影響. 中國中西醫結合雜志 1995;15(1):36-7.
  11. 金京娥, 閔永基, 李昊燮, 柳道坤. 五苓散煎湯液의 胃內 直接投與가 白鼠의 腎臟機能과 血漿 Renin 활성도 및 Atrial Natriuretic Peptide 濃度에 미치는 影響. 동의생리학회지 1996;11(2):89-98.
  12. 金洸洙. 五苓散, 補中益氣湯, 蔘苓白朮散이 Mesanial Cell 증식과 Fibronectin 발현에 미치는 影響. 경희대학교 한의학과 석사학위논문. 2000.
  13. 大西 憲明, 長澤 一樹, 橫山 照由. モデルマウスを用いた漢方方劑の利水作用の檢証. 和漢醫藥學雜誌 2000;17:131-6.
  14. 赤瀨朋秀, 眞崎義彦, 加賀谷肇, 遠藤忠雄, 田代眞一. 單離灌流腎を用いたラット腎に對する五苓散の藥理效果に關する經驗的檢討. 和漢醫藥學雜誌 2000;17:215-20.
  15. 織田 眞智子, 前田 佳奈, 東野 英明. 五苓散及び 構成生藥 1 拔き處方のピュ一ロマイシンアミノヌクレオシド(PA)腎障害に及ぼす作用. 和漢醫藥學雜誌 2002;19(Supplement):60.
  16. 韓宇萍, 王宁生, 宓穗卿. 五苓散對阿霉素型腎病綜合征大鼠治療作用的實驗硏究. 中藥新藥汝臨床藥理 2003;14(4):223-7.
  17. 何嵐, 陣朝暉, 徐月紅, 王宁生. 五苓散含藥血淸對大鼠系膜細胞增殖性及細胞外基質的影響. 中藥材 2006;29(8):819-20.
  18. 何嵐, 彭波, 陣朝暉, 蔡宇, 歐明. 五苓散保護阿霉素腎病大鼠腎小球濾過屛障的實驗硏究. 中藥材 2006;29(3):272-4.
  19. 何嵐, 王宁生. 五苓散減輕阿霉素腎病大鼠蛋白尿的實驗硏究. 中成藥 2006;28(10):1532-4.
  20. 何嵐, 蔡宇, 陣朝暉, 蔣建敏, 王宁生. 五苓散對阿霉素腎病大鼠腎臟血流動力學的影響. 中國中藥雜志 2006;31(16):1358-60.
  21. 何嵐, 蔡宇, 陣朝暉, 胡海燕, 王宁生. 五苓散對阿霉素腎病大鼠腎組織內皮素A型受体表達的影響. 中成藥 2007;29(7):963-6.
  22. He L, Rong XL, Jiang JM, Liu PQ, Li YH. Amelioration of anti-cancer agent adriamycininduced nephrotic syndrome in rats by Wulingsan (Gorei-San), a blended traditional Chinese herbal medicine. Food Chem Toxicol 2008;46:1452-60. https://doi.org/10.1016/j.fct.2007.12.005
  23. 安裕美. Oryeongsan has different effects on water and electrolyte balance by routes of administration. 원광대학교 한의학전문대학원 석사논문. 2010.
  24. Kurita T, Nakamura K, Tabuchi M, Orita M, Ooshima M, Higashino H. Effects of Gorei-san: A Traditional Japanese Kampo Medicine, on Aquaporin 1, 2, 3, 4 and V2R mRNA Expression in Rat Kidney and Forebrain. J Med Sci 2011;11(1):30-8. https://doi.org/10.3923/jms.2011.30.38
  25. 松原 利行, 上野 美穗, 薺藤 晴夫. 腦卒中易發性高血壓ラット(SHRSP) における五苓散の腦卒中予防效果. The general meeting of Medical and Pharmaceutical Society for Wakan-yaku 1993;10:46.
  26. 張仲一, 高嵐. 五苓散對大白鼠實驗性急性腎型高血壓影響的實驗觀察. 天津中醫 1994;11(4):29-30.
  27. 織田 眞智子, 前田 佳奈, 東野 英明. Deoxycorticosterone acetate(DOCA)-食塩高血壓ラットに對する五苓散, 柴苓湯の作用. The general meeting of Medical and Pharmaceutical Society for Wakan-yaku 1999;16:102.
  28. 前田 佳奈, 織田 眞智子, 平野 治男, 山本 由紀子, 東野 英明. 腦卒中易發症性高血壓自然發症ラット(SHRSP) に對する五苓散, 柴苓湯の作用. The general meeting of Medical and Pharmaceutical Society for Wakan-yaku 1999;16:101.
  29. 前田 佳奈, 織田 眞智子, 東野 英明. 腦卒中易發症性高血壓自然發症ラット(SHRSP) に對する五苓散.柴苓湯の生体內水の動態に及ぼす作用. 和漢醫藥學雜誌 2000;17:81.
  30. 織田 眞智子, 前田 佳奈, 東野 英明, 平野 治男, 山本 由紀子. 五苓散變方および柴苓湯の腦卒中易發症性高血壓自然發症ラット(SHRSP) における水代謝調節作用. 和漢醫藥學雜誌 2000;17:157-64.
  31. 韓宇萍, 王宁生, 宓穗卿, 劉啓德. 五苓散對腎性高血壓大鼠降壓作用的實驗硏究. 中西醫結合學報 2003;1(4):285-8.
  32. 前田 佳奈, 織田 眞智子, 平野 治男, 東野 英明. Deoxycorticosterone acetate(DOCA)誘發高血壓ラットに對する漢方藥 : 五苓散變方および柴苓湯の作用. 和漢醫藥學雜誌 2003;20(2):74-81.
  33. 大島 佳奈, 東野 英明. 生体內水の動態に及ぼす五苓散の作用(一般演題抄錄, 第55回近畿大學醫學會學術講演會). 近畿大醫誌 2004;29(1):22A.
  34. 李春娟, 徐太生, 馮占榮, 金東明. 仲景五苓散法對實驗性代謝綜合征大鼠高血壓的影響. 吉林中醫藥 2007;27(5):56.
  35. 李春娟, 金東明. 五苓散治療代謝性高血壓的實驗硏究.吉林中醫藥 2008;28(2):150-1.
  36. 36. Kiga C, Goto H, Sakurai H, Hayashi K, Hikiami H, Shimada Y, et al. Effects of traditional Japanese(Kampo) medicines(orengedokuto, goreisan and shichimotsukokato) on the onset of stroke and expression patterns of plasma proteins in spontaneously hypertensive stroke-prone rats. 和漢醫藥學雜誌 2008;25(5/6):125-32.
  37. 秋山 一誠, 織田 眞智子, 中西 由香, 阿部 博子. $CCl_4$ 肝障害に對する利水劑(五苓散)の作用第 1報. The general meeting of Medical and Pharmaceutical Society for Wakan-yaku 1993;10:71.
  38. 織田 眞智子, 秋山 一誠, 中西 由香, 阿部 博子. $CCl_4$ 肝障害に對する利水劑(五苓散)の作用第 2報. The general meeting of Medical and Pharmaceutical Society for Wakan-yaku 1993;10:72.
  39. 織田 眞智子, 中西 由香, 唐方, 阿部 博子. $CCl_4$ 肝障害に對する利水劑(五苓散)の作用. The general meeting of Medical and Pharmaceutical Society for Wakan-yaku 1995;12:42.
  40. 신흥묵, 김호현, 김길훤, 신억섭. 五苓散의 전처치가 $CCl_4$ 投與로 인한 흰쥐의 肝의 SOD 活性 및 過酸化脂質 含量에 미치는 影響. 동의생리학회지 1996;11(1):171-80.
  41. 권오성, 최흥식, 이준희, 강윤호. 五苓散이 $CCl_4$ 投與로 인한 흰쥐의 損傷肝에 미치는 影響. 한의학연구소 논문집 1996;5(1):131-47.
  42. 이준희, 강윤호. 五苓散이 Galactosamine 誘導肝毒性 흰쥐의 Antioxidant Enzyme 活性과 Lipid peroxidation에 미치는 影響. 대한한방내과학회지 1997;18(1):218-30.
  43. 織田眞智子, 中西由香, 唐 方, 阿部博子. $CCl_4$肝障害に對する五苓散の作用. 和漢醫藥學雜誌 1998;15(1):78-82.
  44. 金貞娟. 五苓散과 五苓散加蒼朮이 肥滿 白鼠의 體重에 미치는 影響. 원광대학교 한의학과 석사학위 논문. 1993.
  45. 白炅龍. 五芩散이 Dexamethasone등으로 誘導된 adipocyte에 미치는 影響. 원광대학교 한의학과 석사학위 논문. 1995.
  46. 李相奉. 五苓散이 肥滿誘導 흰쥐의 체중 및 血淸脂質에 미치는 영향. 동국대학교 한의학과 석사학위 논문. 1996.
  47. 林瑩鎬. 五苓散이 肥滿誘導 白鼠의 肝과 副睾丸周圍의 脂肪組織, 血淸脂質 및 尿中 Hormone의 變化에 關한 硏究. 원광대학교 한의학과 박사학위 논문. 1998.
  48. 上川床總一郞, 所敬東洋, 浜崎秀久, 石田明允. ウシ毛樣体筋に對する漢方製劑の作用. 日本眼科學會雜誌 1994;98(11):1061-6.
  49. 植田 孝子, 植田 俊彦, Donald A, 福田 紹平, 本宮 有希子, 荒井 裕一朗, et al. 角膜新生血管モデルにおける柴苓湯, 五苓散または小柴胡湯 の效果. 和漢醫藥學會大會要旨集 1997;14:129.
  50. 山田 利津子, 上野 聰樹, 山田 誠一. 網膜浮腫改善劑五苓散投汝後の家兎眼窩內動脈の血流動態. 和漢醫藥學雜誌 2002;19(Supplement):72.
  51. 森元 康夫, 阪田 美智子, 大野 晶子, 前河 智子, 田島 滋. 糖尿病動物KKAyマウスの血糖値, 飮水量及び尿量に對する白虎加人參湯, 防風通聖散及び五苓散の作用.藥學雜誌 2002;122(2):163-8.
  52. 신은정, 최한별, 한은정, 정성현. 오령산의 피오글리타존 부작용 경감 효과. 약학회지 2007;51(5):307-12.
  53. Liua IM, Tzeng TF, Liou SS, Chang CJ. The amelioration of streptozotocin diabetes-induced renal damage by Wu-Ling-San(Hoelen Five Herb Formula), a traditional Chinese prescription. J Ethnopharmacol 2009;124:211-8. https://doi.org/10.1016/j.jep.2009.04.021
  54. 劉洋, 蘇鳳哲, 徐華洲, 于文燾. 五苓散對腹瀉模型小鼠結腸AQP-4mRNA表達的影響. 中國中醫基出醫學雜志 2005;11(3):197-8.
  55. 岡村 信幸, 高山 健人, 海田 朋美. 塩類下劑誘發下痢モデルマウスに對する五苓散の效果. 日本東洋醫學雜誌 2009;60(5):493-501.
  56. 高立云, 胡格, 楊佐君, 段慧琴, 周宏超, 穆祥. 中藥方劑五苓散對SLT-2e影響大鼠腸黏膜微血管內皮細胞分泌NO的觀察. 中獸醫醫藥雜志 2008;27(6):17-9.
  57. 李岩, 麻樹人. 五苓散對小鼠胃排空及小腸推進功能的影響. 中華消化雜志 1997;17(1):9.
  58. 伊丹 孝文, 江馬 眞, 坂本 純, 細田 勝子, 野口衛, 川崎 浩之進. 細菌內毒素による發熱ウサギを用いた漢方方劑の解熱作用の檢討. 藥學雜誌1992;112(2):129-34.
  59. 張銀卿, 王宁生, 劉啓德, 叶少梅, 歐衛平. 五苓散的毒性評价. 中國現代藥物應用 2008;2(12):16-8.
  60. Pitts RF, Duggan JJ, Miner P. Studies on diuretics. II. The relationship between glomerular filtration rate, proximal tubular absorption of sodium and diuretic efficacy of mercurials. J Clin Invest 1950;29(3):372-9. https://doi.org/10.1172/JCI102268
  61. Matsukawa T, Miyamoto T. Angiotensin II-stimulated secretion of arginine vasopressin is inhibited by atrial natriuretic peptide in humans. Am J Physiol Regul Integr Comp Physiol 2011;300(3) :624-9. https://doi.org/10.1152/ajpregu.00324.2010
  62. Boldt J, Suttner SW. Physiology and Pathophysiology of the Natriuretic Peptide System. Yearbook of Intensive Care and Emergency Medicine 2006; 3:101-9.
  63. Tamma G, Procino G, Svelto M, Valenti G. Cell culture models and animal models for studying the patho-physiological role of renal aquaporins. Cell Mol Life Sci 2011. DOI: 10.1007/s00018-011-0903-3.
  64. Alarifia S, Al-Doaiss A, Alkahtani S, Al-Farraj SA, Al-Eissa MS, Al-Dahmash B, et al. Blood chemical changes and renal histological alterations induced by gentamicin in rats. Saudi Journal of Biological Sciences 2012;19(1):103-10. https://doi.org/10.1016/j.sjbs.2011.11.002
  65. Duner F, Lindstrom K, Hultenby K, Hulkko J, Patrakka J, Tryggvason K, et al. Permeability, Ultrastructural Changes, and Distribution of Novel Proteins in the Glomerular Barrier in Early Puromycin Aminonucleoside Nephrosis. Nephron Exp Nephrol 2010;116:42-52. https://doi.org/10.1159/000317130
  66. 保莉, 羅紅艶, 鄭亞莉. 單次尾淀脉注射嘌呤霉素安基核甘制作大鼠腎病模型的硏究和評价. 宁夏醫學雜志 2011;8:689-91.
  67. Morita Y, Homma Y, Igarashi M, Miyano R, Yamaguchi H, Matsuda M, et al. Decrease in glomerular filtration rate by plasma low-density lipoprotein cholesterol in subjects with normal kidney function assessed by urinalysis and plasma creatinine. Atherosclerosis 2010;210(2) :602-6. https://doi.org/10.1016/j.atherosclerosis.2009.12.025
  68. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease(Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377(9784):2181-92. https://doi.org/10.1016/S0140-6736(11)60739-3
  69. Goruppi S, Bonventre JV, Kyriakis JM. Signaling pathways and late-onset gene induction associated with renal mesangial cell hypertrophy. EMBO J 2002;21(20):5427-36. https://doi.org/10.1093/emboj/cdf535
  70. Gomez-Garre D, Ruiz-Ortega M, Ortego M, Largo R, Lopez-Amanda MJ, Plaza JJ, et al. Effects and interactions of endothelin-1 and angiotensin II on matrix protein expression and synthesis and mesangial cell growth. Hypertension 1996;27:885-92. https://doi.org/10.1161/01.HYP.27.4.885
  71. Mene P. Physiology and pathophysiology of the mesangial cell. Nefrologia 1996;14:8-13.
  72. 趙洪雯, 余榮杰, 彭侃夫, 李斂, 干磊, 吳雄飛. 大鼠阿霉素腎病超微結鉤轉變過程實驗硏究. 重慶醫學 2008;37(8):798-9.
  73. Jeansson M, Bjorck K, Tenstad O, Haraldsson B. Adriamycin Alters Glomerular Endothelium to Induce Proteinuria. J Am Soc Nephrol 2009;20:114-22. https://doi.org/10.1681/ASN.2007111205
  74. 고철우. 신사구체 기저막의 Heparan Sulfate Proteoglycan(HSPG). 소아과 1996;39(12):1643-52.
  75. Welsh GI, Saleem MA. Nephrin - signature molecule of the glomerular podocyte?. J Pathol 2010;220;328-37.
  76. Neil S. Sheerin. A Novel Role for Nephrin in the Maintenance of Glomerular Structure. J Am Soc Nephrol 2009;20:1661-3. https://doi.org/10.1681/ASN.2009060596
  77. Gao X, Xu H, Liu H, Rao J, Li Y, Zha X. Angiopoietin-like protein 3 regulates the motility and permeability of podocytes by altering nephrin expression in vitro. Biochem Biophys Res Commun 2010;399:31-6. https://doi.org/10.1016/j.bbrc.2010.07.027
  78. Ren Z, Liang W, Chen C, Yang H, Singhal PC, Ding G. Angiotensin II induces nephrin dephosphorylation and podocyte injury: Role of caveolin-1. Cell Signal 2012;24(2):443-50. https://doi.org/10.1016/j.cellsig.2011.09.022